Saruc M.Kursat S.Kiliccioglu B.2024-07-222024-07-22199810165134http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20654Diabetic nephropathy is the single most common cause of renal failure leading to end stage renal disease. The cost of providing dialysis for uremic diabetics is very expensive. Diabetic nephropathy is also associated with markedly increased morbidity and mortality for the patient with diabetes mellitus who develops this complication. Angiotensin converting enzyme inhibition has protective effects on renal functions and structure in diabetic nephropathy. This protection is probably independent of the systemic hypotensive effect of these agents. That is why effective antihypertensive treatment with angiotensin converting enzyme inhibitors in patients with diabetic nepropathy results in a large reduction in albuminuria and a low rate of decline in kidney function. As a conclusion, all patients with diabetes and documented diabetic glomerulopathy should be treated with an angiotensin converting enzyme inhibitor.Turkishdipeptidyl carboxypeptidase inhibitorantihypertensive therapydiabetic nephropathydialysishumankidney failureproteinuriashort surveyuremiaShort survey